Logo image of KZIA

KAZIA THERAPEUTICS-SPON ADR (KZIA) Stock Fundamental Analysis

NASDAQ:KZIA - Nasdaq - US48669G3039 - ADR - Currency: USD

3.8  +0.02 (+0.53%)

Fundamental Rating

1

Overall KZIA gets a fundamental rating of 1 out of 10. We evaluated KZIA against 560 industry peers in the Biotechnology industry. KZIA has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, KZIA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year KZIA has reported negative net income.
In the past year KZIA has reported a negative cash flow from operations.
KZIA had negative earnings in each of the past 5 years.
KZIA had a negative operating cash flow in each of the past 5 years.
KZIA Yearly Net Income VS EBIT VS OCF VS FCFKZIA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of KZIA (-124.06%) is worse than 80.89% of its industry peers.
Industry RankSector Rank
ROA -124.06%
ROE N/A
ROIC N/A
ROA(3y)-88.87%
ROA(5y)-67.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KZIA Yearly ROA, ROE, ROICKZIA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600

1.3 Margins

KZIA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KZIA Yearly Profit, Operating, Gross MarginsKZIA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200K -400K -600K -800K -1M

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for KZIA has been increased compared to 1 year ago.
KZIA has more shares outstanding than it did 5 years ago.
KZIA has a worse debt/assets ratio than last year.
KZIA Yearly Shares OutstandingKZIA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
KZIA Yearly Total Debt VS Total AssetsKZIA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

KZIA has an Altman-Z score of -11.73. This is a bad value and indicates that KZIA is not financially healthy and even has some risk of bankruptcy.
KZIA has a worse Altman-Z score (-11.73) than 76.61% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.73
ROIC/WACCN/A
WACCN/A
KZIA Yearly LT Debt VS Equity VS FCFKZIA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 0.24 indicates that KZIA may have some problems paying its short term obligations.
KZIA's Current ratio of 0.24 is on the low side compared to the rest of the industry. KZIA is outperformed by 95.36% of its industry peers.
KZIA has a Quick Ratio of 0.24. This is a bad value and indicates that KZIA is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.24, KZIA is not doing good in the industry: 95.18% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.24
Quick Ratio 0.24
KZIA Yearly Current Assets VS Current LiabilitesKZIA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

5

3. Growth

3.1 Past

KZIA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 92.00%, which is quite impressive.
Looking at the last year, KZIA shows a very strong growth in Revenue. The Revenue has grown by 10211.56%.
KZIA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 87.69% yearly.
EPS 1Y (TTM)92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.77%
Revenue 1Y (TTM)10211.56%
Revenue growth 3Y-46.59%
Revenue growth 5Y87.69%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -55.13% on average over the next years. This is quite bad
Based on estimates for the next years, KZIA will show a quite strong growth in Revenue. The Revenue will grow by 16.21% on average per year.
EPS Next Y-236463.64%
EPS Next 2Y-3300.8%
EPS Next 3Y-864.58%
EPS Next 5Y-55.13%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y16.21%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
KZIA Yearly Revenue VS EstimatesKZIA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2029 2030 2031 2032 50M 100M 150M 200M
KZIA Yearly EPS VS EstimatesKZIA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KZIA. In the last year negative earnings were reported.
Also next year KZIA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KZIA Price Earnings VS Forward Price EarningsKZIA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KZIA Per share dataKZIA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

A cheap valuation may be justified as KZIA's earnings are expected to decrease with -864.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3300.8%
EPS Next 3Y-864.58%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KZIA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KAZIA THERAPEUTICS-SPON ADR

NASDAQ:KZIA (5/30/2025, 8:10:45 PM)

3.8

+0.02 (+0.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-20 2025-02-20
Earnings (Next)N/A N/A
Inst Owners13.93%
Inst Owner Change-57.9%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap21.24M
Analysts82.86
Price Target56.36 (1383.16%)
Short Float %N/A
Short Ratio0.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)400%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-400%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.25
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.28
EYN/A
EPS(NY)-17.04
Fwd EYN/A
FCF(TTM)-1.1
FCFYN/A
OCF(TTM)-1.1
OCFYN/A
SpS0.27
BVpS-1.15
TBVpS-2.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -124.06%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-88.87%
ROA(5y)-67.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.24
Quick Ratio 0.24
Altman-Z -11.73
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.77%
EPS Next Y-236463.64%
EPS Next 2Y-3300.8%
EPS Next 3Y-864.58%
EPS Next 5Y-55.13%
Revenue 1Y (TTM)10211.56%
Revenue growth 3Y-46.59%
Revenue growth 5Y87.69%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y16.21%
EBIT growth 1Y-13.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.91%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.78%
OCF growth 3YN/A
OCF growth 5YN/A